Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors

  • Bioorg Med Chem Lett. 2020 Oct 15;30(20):127479. doi: 10.1016/j.bmcl.2020.127479.
Ning-Yu Wang  1 Wei-Qiong Zuo  2 Rong Hu  3 Wan-Li Wang  3 Yong-Xia Zhu  2 Ying Xu  2 Luo-Ting Yu  2 Zhi-Hao Liu  4
Affiliations
  • 1. School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China. Electronic address: [email protected].
  • 2. Lab of Medicinal Chemistry, Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.
  • 3. School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
  • 4. Lab of Medicinal Chemistry, Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China. Electronic address: [email protected].
Abstract

Two classes of piperazinone-containing thieno[3,2-d]pyrimidines were designed and synthesized as new PI3Kδ inhibitors in this study. Detailed SAR study with respect to the piperazinone substituents at the 6-position of thieno[3,2-d]pyrimidine core demonstrated that piperazinone-containing thieno[3,2-d]pyrimidines would be more potent and selective for PI3Kδ than their piperazine counterparts, which led to the discovery of several potent PI3Kδ inhibitors with comparable or better antiproliferative activity against a panel of non-Hodgkin lymphoma (NHL) cell lines as compared with idelalisib. Our study will promote the development of new PI3Kδ inhibitors based on piperazinone-containing thieno[3,2-d]pyrimidine scaffold.

Keywords
Antiproliferative activity; PI3Kδ; Piperazinone; SAR; Thieno[3,2-d]pyrimidine.